Literature DB >> 3255915

Chlortenoxicam pharmacokinetics in young and elderly human volunteers.

S I Ankier1, A E Brimelow, P Crome, A Johnston, S J Warrington, P Turner, H P Ferber.   

Abstract

The pharmacokinetics of chlortenoxicam, a new non-steroidal anti-inflammatory drug, have been compared in young and elderly healthy human volunteers. Chlortenoxicam was found to have a relatively short mean elimination half-life of about 4 hours, with considerable inter-subject variability, but there was no significant difference between young and elderly subjects. There was no evidence of accumulation with repeated administration. No unchanged chlortenoxicam was found in urine from any subject, suggesting that it undergoes extensive metabolism in man.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3255915      PMCID: PMC2429000          DOI: 10.1136/pgmj.64.756.752

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  3 in total

1.  STRIPE: an interactive computer program for the analysis of drug pharmacokinetics.

Authors:  A Johnston; R C Woollard
Journal:  J Pharmacol Methods       Date:  1983-05

2.  Influence of disease on drug toxicity.

Authors:  P Turner
Journal:  Arch Toxicol Suppl       Date:  1984

Review 3.  Non-steroidal anti-inflammatory drugs. Current status and rational therapeutic use.

Authors:  F D Hart; E C Huskisson
Journal:  Drugs       Date:  1984-03       Impact factor: 9.546

  3 in total
  11 in total

1.  Clinical trials in elderly subjects.

Authors:  P Turner
Journal:  Postgrad Med J       Date:  1989-04       Impact factor: 2.401

2.  Effects of lornoxicam on the hemodynamic and catecholamine response to laryngoscopy and tracheal intubation.

Authors:  Mohamed Daabiss; Mohamed Hashish
Journal:  Eur J Clin Pharmacol       Date:  2011-03-03       Impact factor: 2.953

3.  Lornoxicam, indomethacin and placebo: comparison of effects on faecal blood loss and upper gastrointestinal endoscopic appearances in healthy men.

Authors:  S J Warrington; N M Debbas; M Farthing; M Horton; A Johnston; A Thillainayagam; P Turner; H Ferber
Journal:  Postgrad Med J       Date:  1990-08       Impact factor: 2.401

4.  A double blind, multicentre, placebo controlled trial of lornoxicam in patients with osteoarthritis of the hip and knee.

Authors:  H Berry; H A Bird; C Black; D R Blake; A M Freeman; D N Golding; E B Hamilton; M I Jayson; B Kidd; H Kohn
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

5.  Safety of lornoxicam in the treatment of postoperative pain: a post-marketing study of analgesic regimens containing lornoxicam compared with standard analgesic treatment in 3752 day-case surgery patients.

Authors:  Narinder Rawal; Karsten Krøner; Marija Simin-Geertsen; Charlotte Hejl; Rudolf Likar
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

Review 6.  Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions.

Authors:  J A Balfour; A Fitton; L B Barradell
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

7.  A pharmacokinetic interaction between cimetidine or ranitidine and lornoxicam.

Authors:  M Ravic; I Salas-Herrera; A Johnston; P Turner; K Foley; D E Rosenow
Journal:  Postgrad Med J       Date:  1993-11       Impact factor: 2.401

Review 8.  Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents.

Authors:  K T Olkkola; A V Brunetto; M J Mattila
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

Review 9.  Clinical pharmacokinetics of lornoxicam. A short half-life oxicam.

Authors:  N M Skjodt; N M Davies
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

10.  Comparison of chlortenoxicam and indomethacin on frusemide-induced diuresis.

Authors:  A Hitoglou-Makedou; M Lawson; P Turner; H P Ferber
Journal:  Postgrad Med J       Date:  1989-11       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.